Haemophilia B in Algeria: Realities and therapeutic perspectives.
Nekkal MS, Mesli N, Grifi F, Cherif N, Ouchenane Z, Bettayeb MS.
Haemophilia. 2023 Sep;29(5):1176-1183. doi: 10.1111/hae.14827. Epub 2023 Jul 19.
Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH): a multicentre, open-label, randomised phase 3 trial.
Young G, Srivastava A, Kavakli K, Ross C, Sathar J, You CW, Tran H, Sun J, Wu R, Poloskey S, Qiu Z, Kichou S, Andersson S, Mei B, Rangarajan S.
Lancet. 2023 Apr 29;401(10386):1427-1437. doi: 10.1016/S0140-6736(23)00284-2. Epub 2023 Mar 29.
Haemophilia B: Where are we now and what does the future hold?
Dolan G, Benson G, Duffy A, Hermans C, Jiménez-Yuste V, Lambert T, Ljung R, Morfini M, Zupančić Šalek S.
Blood Rev. 2018 Jan;32(1):52-60. doi: 10.1016/j.blre.2017.08.007. Epub 2017 Aug 16.
Concizumab prophylaxis in people with haemophilia A or haemophilia B without inhibitors (explorer8): a prospective, multicentre, open-label, randomised, phase 3a trial.
Chowdary P, Angchaisuksiri P, Apte S, Astermark J, Benson G, Chan AKC, Jiménez Yuste V, Matsushita T, Høgh Nielsen AR, Sathar J, Sutton C, Šaulytė Trakymienė S, Tran H, Villarreal Martinez L, Wheeler AP, Windyga J, Young G, Thaung Zaw JJ, Eichler H.
Lancet Haematol. 2024 Dec;11(12):e891-e904. doi: 10.1016/S2352-3026(24)00307-7. Epub 2024 Nov 6.
Fitusiran prophylaxis in people with severe haemophilia A or haemophilia B without inhibitors (ATLAS-A/B): a multicentre, open-label, randomised, phase 3 trial.
Srivastava A, Rangarajan S, Kavakli K, Klamroth R, Kenet G, Khoo L, You CW, Xu W, Malan N, Frenzel L, Bagot CN, Stasyshyn O, Chang CY, Poloskey S, Qiu Z, Andersson S, Mei B, Pipe SW.
Lancet Haematol. 2023 May;10(5):e322-e332. doi: 10.1016/S2352-3026(23)00037-6. Epub 2023 Mar 29.
Haemophilia.
Chowdary P, Carcao M, Kenet G, Pipe SW.
Lancet. 2025 Mar 1;405(10480):736-750. doi: 10.1016/S0140-6736(24)02139-1.
Haemophilias A and B.
Bolton-Maggs PH, Pasi KJ.
Lancet. 2003 May 24;361(9371):1801-9. doi: 10.1016/S0140-6736(03)13405-8.
Etranacogene dezaparvovec gene therapy for haemophilia B (HOPE-B): 24-month post-hoc efficacy and safety data from a single-arm, multicentre, phase 3 trial.
Coppens M, Pipe SW, Miesbach W, Astermark J, Recht M, van der Valk P, Ewenstein B, Pinachyan K, Galante N, Le Quellec S, Monahan PE, Leebeek FWG; HOPE-B Investigators.
Lancet Haematol. 2024 Apr;11(4):e265-e275. doi: 10.1016/S2352-3026(24)00006-1. Epub 2024 Mar 1.
The past and future of haemophilia: diagnosis, treatments, and its complications.
Peyvandi F, Garagiola I, Young G.
Lancet. 2016 Jul 9;388(10040):187-97. doi: 10.1016/S0140-6736(15)01123-X. Epub 2016 Feb 18.
[Haemophilia A and B in dogs].
Mischke R.
Tierarztl Prax Ausg K Kleintiere Heimtiere. 2012;40(1):44-53; quiz 54.
